Remote screening of diabetic retinopathy can help in early detection, even before there are any noticeable vision changes
Ranluspec is the only interchangeable ranibizumab biosimilar approved in the United States in both vial and pre-filled syringe (PFS) presentations
The device screens for conditions like diabetic retinopathy, glaucoma, age-related macular degeneration, cataract and refractive error, in under ten minutes per patient
By leveraging digital screening and remote consultation, the medical community is moving beyond the confines of the clinic
The acquisition gives Bayer full rights to PER-001, an experimental therapy now in Phase II clinical trials for Glaucoma and Diabetic Retinopathy
VESCOP, ENTOD Pharmaceuticals, and APTI-MSB host the event to bridge lab-to-clinic gap in eye care
ANYRA is India’s first indigenously developed Aflibercept 2 mg biosimilar
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
Subscribe To Our Newsletter & Stay Updated
